The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain.
Herein we review our progress on the development of phosphopeptide-based prodrugs targeting the SH2 domain of STAT3 to prevent recruitment to cytokine and growth factor receptors, activation, nuclear translocation and transcription of genes involved in cancer. We developed high affinity phosphopeptides (K I = 46-200 nM). Corresponding prodrugs inhibited constitutive and IL-6 induced Tyr705 phosphorylation at 0.5-1 μM in a variety of human cancer cell lines. They were not cytotoxic at 5 μM in vitro but they inhibited tumor growth in a human xenograft breast cancer model in mice, accompanied by reduced VEGF expression and angiogenesis.
The Department of Experimental Therapeutics; The University of Texas MD Anderson Cancer Center; Houston, TX USA.
John S
JS
McMurray
Pijus K
PK
Mandal
Warren S
WS
Liao
Jim
J
Klostergaard
Fredika M
FM
Robertson
SH2 domain; STAT3; peptidomimetic; phosphopeptide; prodrug